HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Sun Pharma, CMS ink licensing agreement for generic products in Mainland China
Aug-17-2019

Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has granted an exclusive license to a subsidiary of China Medical System Holdings (CMS) to develop and commercialize seven generic products in Mainland China. The collaboration with CMS now covers eight generic products including the seven products referred above. The total addressable market size for all these eight products is about $1 billion (as per recent IQVIA data) in Mainland China.

The initial term of the agreement shall be 20 years from the first commercial sale of the respective products in Mainland China and may be extended for additional three years' as per mutual agreement of the two parties.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

  RELATED NEWS >>